Tectonic Therapeutic

Clinical-stage biotech, GPCR-targeted biologics

TECX · Nasdaq · United States

Share price · TECX

$21.04-15.57 (-42.53%) 3M

close as of 2026-11-18 · 24h delayed · vol 169K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TECX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 31 Aug 2026-15.9%

    Nothing announced by TECX that day or the session before.

  2. 18 Aug 2026+8.2%

    Nothing announced by TECX that day or the session before.

  3. 12 Aug 2026+15.6%

    Nothing announced by TECX that day or the session before.

  4. 15 Jul 2026-6.6%

    Nothing announced by TECX that day or the session before.

  5. 6 Jul 2026-7.1%

    Nothing announced by TECX that day or the session before.

  6. 2 Jul 2026+15.9%

    Nothing announced by TECX that day or the session before.

  7. 6 Mar 2026+28.8%

    Nothing announced by TECX that day or the session before.

  8. 4 Mar 2026+12.4%

    Nothing announced by TECX that day or the session before.

  9. 3 Mar 2026+6.1%
  10. 25 Feb 2026+8.2%

Share of unusual movement by asset

For each asset, the share of TECX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Fc-relaxin fusion protein (TX45)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—53%
Sessions with no dated event—47%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Relaxin receptor (RXFP1) / relaxinProtein / enzyme therapeutic
Pulmonary Hypertension Associated with Interstitial Lung DiseasePulmonary Hypertension due to Left Heart Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Fc-relaxin fusion protein (TX45)Phase 2Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Est. primary completion 2026-11-24 · NCT06616974 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2025Topline resultFc-relaxin fusion protein (TX45)TX45 Phase 1b Part B topline results in PH-HFrEF

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$17M$235M$21M-$15M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$18M$228M$22M-$21M operating cash flowreport ↗
2026-Q1—$21M$237M$25M-$18M operating cash flowreport ↗
2025-Q3—$17M$270M$19M-$18M operating cash flowreport ↗
2025-Q2—$17M$288M$20M-$15M operating cash flowreport ↗
2025-Q1—$13M$307M$16M-$13M operating cash flowreport ↗
2024-Q3—$14M$160M$18M-$20M operating cash flowreport ↗
2024-Q2—$7.1M$186M$13M-$15M operating cash flowreport ↗
2024-Q1—$0.7M$91M$6.8M-$7.6M operating cash flowreport ↗
2023-Q3—$15M$107M$22M-$20M operating cash flowreport ↗
2023-Q2—$11M$125M—-$15M operating cash flowreport ↗
2023-Q1—$17M$73M$25M-$20M operating cash flowreport ↗
2022-Q3—$16M$116M$23M-$16M operating cash flowreport ↗
2022-Q2—$19M$133M$28M-$29M operating cash flowreport ↗
2022-Q1—$19M$162M$30M-$28M operating cash flowreport ↗
2021-Q3—$23M$202M$33M-$25M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$63M$255M$19M-$60M operating cash flowreport ↗

For full-year 2025, Tectonic Therapeutic did not disclose revenue. Research and development expenses were $63.49M, up 53.5% YoY, and cash and cash equivalents were $254.87M. The company reported a net loss of $74.15M for the year.

The company stated its cash position is expected to provide runway into Q4 2028. Clinical developments include positive topline results from the TX45 Phase 1b trial in Group 2 PH-HFrEF announced in October 2025, the first subject randomized in the TX2100 Phase 1a trial in HHT in February 2026, and the activation of the TX45 Phase 2 trial in PH-ILD in February 2026. Tectonic also expects topline results from the TX2100 Phase 1a trial in Q4 2026 and from the TX45 APEX Phase 2 trial in 2026, and announced the appointment of François Nader, M.D., MBA, as an independent director and incoming Board Chair, effective April 1, 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$41M$142M$15M-$59M operating cash flowreport ↗
2023-FY—$48M$99M—-$63M operating cash flowreport ↗
2022-FY—$72M$93M$26M-$97M operating cash flowreport ↗
2021-FY—$83M$190M$30M-$98M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($235K), 11 sales ($651K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-26REICIN ALISE · director, Chief Executive OfficerOption exercise10,000$2.38$24KForm 4
2026-10-26REICIN ALISE · director, Chief Executive OfficerOption exercise (derivative)10,000——Form 4
2026-09-30McNamara Peter · Chief Scientific OfficerOpen-market sale536$23.04$12KForm 4
2026-09-25Lochner Daniel · Chief Financial OfficerTax withholding520$23.67$12KForm 4
2026-09-25Schwabish Marc · Chief Business OfficerTax withholding411$23.67$10KForm 4
2026-09-25REICIN ALISE · director, Chief Executive OfficerTax withholding1,545$23.67$37KForm 4
2026-09-25Ruddy Marcella K. · Chief Medical OfficerTax withholding525$23.67$12KForm 4
2026-09-25McNamara Peter · Chief Scientific OfficerTax withholding444$23.67$11KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 111 reporting institutions held 13.8M shares ($411.8M, 69.2% of shares outstanding).

#InstitutionSharesValue
1FMR LLC2,816,494$87.1M
2TCG Crossover Management, LLC1,204,891$37.2M
3Aberdeen Group plc1,141,824$35.3M
4BlackRock, Inc.860,352$26.6M
5BRAIDWELL LP847,151$26.2M
6First Light Asset Management, LLC647,743$20.0M
7BAKER BROS. ADVISORS LP607,788$18.8M
85AM Venture Management, LLC606,660$18.8M
9VANGUARD CAPITAL MANAGEMENT LLC473,532$14.6M
10Vestal Point Capital, LP328,000$10.1M
11KENNEDY CAPITAL MANAGEMENT LLC286,682$8.9M
12GEODE CAPITAL MANAGEMENT, LLC268,273$8.3M
13MARSHALL WACE, LLP229,595$7.1M
14ORBIMED ADVISORS LLC226,600$7.0M
15STATE STREET CORP213,505$6.6M